Paper825035
Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.
Scott RE and 1 other. Antimicrob Agents Chemother, 1976. Cited by 69 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats. Papers, record 825035. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/825035
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Synergistic activity of carbenicillin and gentamicin in experimental Pseudomonas bacteremia in neutropenic rats.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Agranulocytosis | Major topic |
| Carbenicillin | Major topic |
| Gentamicins | Major topic |
| Neutropenia | Major topic |
| Pseudomonas Infections | Major topic |
| Sepsis | Major topic |
| Animals | |
| Drug Synergism | |
| Female | |
| Pseudomonas aeruginosa | |
| Rats | |
| Time Factors |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 13,880,374 | Determinants of infection in the peritoneal cavity. I. Response to and fate of Staphylococcus aureus and Staphylococcus albus in the mouse. | Yale J Biol Med | 1962 | https://conductscience.org/library/papers/13880374 | PubMed |
| 2 | 5,001,622 | Gentamicin: clinical use with carbenicillin and in-vitro studies with recent isolates of Pseudomonas aeruginosa. | J Infect Dis | 1971 | https://conductscience.org/library/papers/5001622 | PubMed |
| 3 | 4,372,051 | Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. | Eur J Cancer (1965) | 1973 | https://conductscience.org/library/papers/4372051 | PubMed |
| 4 | 4,372,050 | Advances in the management of Pseudomonas aeruginosa infections in cancer patients. | Eur J Cancer (1965) | 1973 | https://conductscience.org/library/papers/4372050 | PubMed |
| 5 | 5,001,620 | Pseudomonas bacteremia: pharmacologic and other bases for failure of treatment with gentamicin. | J Infect Dis | 1971 | https://conductscience.org/library/papers/5001620 | PubMed |
| 6 | 4,937,796 | Carbenicillin therapy for pseudomonas infections. | JAMA | 1971 | https://conductscience.org/library/papers/4937796 | PubMed |
| 7 | 4,893,148 | Carbenicillin therapy of gram-negative bacilli infections. | Am J Med Sci | 1969 | https://conductscience.org/library/papers/4893148 | PubMed |
| 8 | 816,976 | Therapy of neutropenic rats infected with Pseudomonas aeruginosa. | J Infect Dis | 1976 | https://conductscience.org/library/papers/816976 | PubMed |
| 9 | 1,101,822 | Feasibility of administering aminoglycoside antibiotics by continuous intravenous infusion. | Antimicrob Agents Chemother | 1975 | https://conductscience.org/library/papers/1101822 | PubMed |
| 10 | 1,159,330 | Gentamicin sulfate pharmacokinetics: lower levels of gentamicin in blood during fever. | J Infect Dis | 1975 | https://conductscience.org/library/papers/1159330 | PubMed |
| 11 | 5,164,949 | Synergy of carbenicillin and gentamicin in experimental infection with Pseudomonas. | J Infect Dis | 1971 | https://conductscience.org/library/papers/5164949 | PubMed |
| 12 | 4,375,433 | Interaction of purulent material with antibiotics used to treat Pseudomonas infections. | Antimicrob Agents Chemother | 1974 | https://conductscience.org/library/papers/4375433 | PubMed |
| 13 | 4,335,448 | Antibiotics for Pseudomonas aeruginosa sepis: inadequate proof of efficacy. | J Infect Dis | 1971 | https://conductscience.org/library/papers/4335448 | PubMed |
| 14 | 4,313,764 | In vitro effects of carbenicillin combined with gentamicin or polymyxin B against Pseudomonas aeruginosa. | Appl Microbiol | 1969 | https://conductscience.org/library/papers/4313764 | PubMed |
| 15 | 4,322,162 | Pseudomonas bacteremia in patients with malignant diseases. | Am J Med Sci | 1970 | https://conductscience.org/library/papers/4322162 | PubMed |
| 16 | 4,213,977 | Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. | J Infect Dis | 1974 | https://conductscience.org/library/papers/4213977 | PubMed |
| 17 | 4,213,872 | Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. | J Infect Dis | 1974 | https://conductscience.org/library/papers/4213872 | PubMed |
| 18 | 4,201,634 | Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center. | Ann Intern Med | 1973 | https://conductscience.org/library/papers/4201634 | PubMed |
| 19 | 4,208,283 | Comparison of gentamicin, carbenicillin and gentamicin, and carbenicillin in Pseudomonas sepsis in monkeys. | Antimicrob Agents Chemother | 1973 | https://conductscience.org/library/papers/4208283 | PubMed |
| 20 | 4,202,683 | Gram-negative infections in cancer. Study of empiric therapy comparing carbenicillin-cephalothin with and without gentamicin. | JAMA | 1974 | https://conductscience.org/library/papers/4202683 | PubMed |
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36,421,304 | Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/36421304 | PubMed |
| 31,589,646 | Replacing plasma membrane outer leaflet lipids with exogenous lipid without damaging membrane integrity. | PLoS One | 2019 | https://conductscience.org/library/papers/31589646 | PubMed |
| 29,463,528 | Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29463528 | PubMed |
| 28,993,331 | Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28993331 | PubMed |
| 8,980,762 | Synergism between tobramycin and ceftazidime against a resistant Pseudomonas aeruginosa strain, tested in an in vitro pharmacokinetic model. | Antimicrob Agents Chemother | 1997 | https://conductscience.org/library/papers/8980762 | PubMed |
| 6,792,982 | Comparative in vitro synergistic activity of new beta-lactam antimicrobial agents and amikacin against Pseudomonas aeruginosa and Serratia marcescens. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6792982 | PubMed |
| 6,517,544 | Synergism at clinically attainable concentrations of aminoglycoside and beta-lactam antibiotics. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6517544 | PubMed |
| 6,329,087 | Comparison of azlocillin, ceftizoxime, cefoxitin, and amikacin alone and in combination against Pseudomonas aeruginosa in a neutropenic-site rabbit model. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6329087 | PubMed |
| 6,315,424 | In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa. | Eur J Clin Microbiol | 1983 | https://conductscience.org/library/papers/6315424 | PubMed |
| 6,289,731 | Comparative synergistic activity of cefoperazone, cefotaxime, moxalactam, and carbenicillin, combined with tobramycin, against Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6289731 | PubMed |
| 6,282,192 | In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/6282192 | PubMed |
| 6,219,619 | Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6219619 | PubMed |
| 3,924,610 | Use of discriminative models of Pseudomonas aeruginosa bacteremia in granulocytopenic rats for testing antimicrobial efficacy. | Eur J Clin Microbiol | 1985 | https://conductscience.org/library/papers/3924610 | PubMed |
| 3,909,952 | Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats. | Antimicrob Agents Chemother | 1985 | https://conductscience.org/library/papers/3909952 | PubMed |
| 3,107,461 | Evaluation of combination chemotherapy in a lightly anesthetized animal model of Pseudomonas pneumonia. | Antimicrob Agents Chemother | 1987 | https://conductscience.org/library/papers/3107461 | PubMed |
| 2,938,945 | Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection. | Eur J Clin Microbiol | 1986 | https://conductscience.org/library/papers/2938945 | PubMed |
| 1,803,987 | Antimicrobial agent therapy for Pseudomonas aeruginosa. | Antimicrob Agents Chemother | 1991 | https://conductscience.org/library/papers/1803987 | PubMed |
| 1,510,412 | In vivo antibiotic synergism: contribution of animal models. | Antimicrob Agents Chemother | 1992 | https://conductscience.org/library/papers/1510412 | PubMed |
| 478,641 | Efficacy of antimicrobial therapy in experimental rat pneumonia: antibiotic treatment schedules in rats with impaired phagocytosis. | Infect Immun | 1979 | https://conductscience.org/library/papers/478641 | PubMed |
| 478,640 | Efficacy of antimicrobial therapy in experimental rat pneumonia: effects of impaired phagocytosis. | Infect Immun | 1979 | https://conductscience.org/library/papers/478640 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/825035
GET https://conductscience.org/api/papers/v1/825035/references?page=2